Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Valeant Pharmaceuticals Intl Inc Is Looking Healthy

By Chris Lau, InvestorPlace Contributor

After Valeant beat expectations, VRX stock soared 17%. The rally is not yet over as the turnaround unfolds.

Sharp Drop Celgene Corporation Stock May Have Just Created an Entry Point

By Chris Lau, InvestorPlace Contributor

Investors are so wary of Celgene's prospects that they overlook the steady growth ahead and potential for CELG stock after 2020.

Brace Yourself When Valeant (VRX) Reports Earnings

By Chris Lau, InvestorPlace Contributor

Valeant's (VRX) stock is falling ahead of its earnings report. Its prospects are far from certain but management is making the right moves.

Facebook Inc Looks to Continue the Tech Trend of Strong Earnings

By Chris Lau, InvestorPlace Contributor

FB stock reports results this week and promises to deliver significant growth again in Facebook's mobile advertising revenue.

Gilead Sciences, Inc. Stock Looks Good Regardless of Quarterly Earnings Report

By Chris Lau, InvestorPlace Contributor

Gilead is an attractive value investing idea, as GILD stock's growth potential will play out in the years to come.

Load More